Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust, shares what politicians and clinical trialists can do to help mitigate cardiovascular health disparities.
Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust, describes the social determinants of health (SDOH) that she sees contributing to cardiovascular health disparities in the United Kingdom and what politicians and clinical trialists can do to help mitigate these issues.
Transcript
What are some SDOH that further contribute to cardiovascular health disparities, and what strategies might mitigate their impact on health outcomes?
There are some changes that need to be implemented by politicians. We need to advocate for our patients and lobby politicians to improve living conditions, minimum wage, and the expectation of access to food for school children. It's something that doesn't strike me on a regular basis, because it's not something I'm exposed to, but we have children in schools in the UK who don't eat a proper meal apart from when they go to school.
So, in fact, if we gave [food] access to all school children, it wouldn't be a huge cost but it would improve the quality of life and the lived experience of children from minority populations and from more deprived populations—it's not only minority populations. And it would improve their health care and then their well-being as they go into adulthood, because if you have poor health care nutrition in childhood, it often leads to poor health outcomes as an adult as well.
So there's lots of things we can think about on an institutional level, but on a personal level, obviously addressing your own bias. We need to make sure that our patients who have more economic challenges are encouraged to enroll in clinical trials and be supportive in that way as well.
We perhaps need to make a quota in research. We're suggesting that now for women. Women are often 20% or 30% of clinical trial participants when they're 50%, 52% of the population. So why isn't it 50/50? Certain conditions impact women at a later age, so if there's an age cutoff, you can understand that there may be less women in the age group being randomized. But actually it's not difficult to find more mixed populations, and I think we need to encourage that. If you encourage trialists to enroll more people of color, then I think we'll get more relevant data.
At ASCO, Testing and AI Rival Drugs for Attention, but Reimbursement Remains a Barrier
July 5th 2025Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time. A feature from our upcoming special issue of Evidence-Based Oncology: our annual ASCO recap.
Read More
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Read More
Racial Disparities in Opioid Use Disorder Treatment After ED Visit for Overdose
July 2nd 2025There are significant racial disparities in outpatient referrals for opioid use disorder treatment, highlighting urgent need for targeted interventions in emergency care, according to a recent study.
Read More